By Mike Montemarano, Associate Editor08.13.21
The U.S. Food and Drug Administration rejected two New Dietary Ingredient Notifications (NDINs) for full-spectrum hemp extracts containing cannabidiol (CBD) submitted by manufacturers Charlotte’s Web and Irwin Naturals. According to industry stakeholders, the decision signifies that FDA does not intend to approve of the use of CBD as a dietary ingredient, and by default, doesn’t intend to regulate it as such.
Notably, these were the first NDI notifications to receive a response from the FDA, making this a new development over the course of deliberations on where the ingredient stands.
“Based on how FDA engaged these companies over the course of months—having meeting after meeting, request after request for more safety data—and then an invitation to submit NDI notifications, we’re certainly disappointed and surprised that FDA rejected the two NDI notifications,” Steve Mister, president and CEO of the Council for Responsible Nutrition, told
FREE SUBSCRIPTION
Notably, these were the first NDI notifications to receive a response from the FDA, making this a new development over the course of deliberations on where the ingredient stands.
“Based on how FDA engaged these companies over the course of months—having meeting after meeting, request after request for more safety data—and then an invitation to submit NDI notifications, we’re certainly disappointed and surprised that FDA rejected the two NDI notifications,” Steve Mister, president and CEO of the Council for Responsible Nutrition, told
Continue reading this story and get 24/7 access to Nutraceuticals World for FREE
FREE SUBSCRIPTION
Already a subscriber? Login
Related Knowledge Center
